随机对照试验的元分析,评估慢性病中内啡素受体对手的有效性和安全性
Yunqi Shi1, Nan Ye, Guoqin Wang
1Division of Nephrology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Clinical journal of the American Society of Nephrology : CJASN
|January 12, 2026
概括
内甲素受体抗剂 (ERA) 在减少蛋白尿和减缓慢性病 (CKD) 患者的病进展方面表现有前途. 虽然ERA可能会增加低血压的风险,但它们似乎不会恶化流体保留或心力衰竭.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 慢性病 (CKD) 对健康构成重大负担.
- 末端素受体抗剂 (ERA) 正在研究它们对治疗CKD的潜力.
- 对ERA的一个关键问题是它们可能导致液体保留.
研究的目的:
- 评估ERAs在减少CKD患者蛋白尿的疗效.
- 评估ERA的安全性,包括液体保留和功能.
- 量化ERA对蛋白尿,功能和CKD中血压的影响.
主要方法:
- 进行了随机对照试验 (RCT) 的元分析.
- 在主要的数据库中进行了搜索,包括科克伦图书馆,奥维德医学线和奥维德数据库.
- 分析了14项涉及6412名患者的试验数据.
主要成果:
- ERA显著降低了尿蛋白与肌素的比率 (UPCR) 和尿蛋白与肌素的比率 (UACR).
- ERAs降低了末期病 (ESKD) 的风险,并改善了估计的球过率 (eGFR) 斜率.
- 虽然ERAs增加了低血压和B型尿素 (BNP) 和体重略微升高的风险,但它们没有增加胀,水分保留或心力衰竭的发生率.
结论:
- ERAs在减少蛋白尿和减缓慢性病进展方面表现出有效性.
- ERA可能是管理CKD的有价值的治疗选择,并仔细监测低血压.
- 进一步的研究可能会探索优化ERA的使用,以最大限度地提高效益,同时最大限度地减少副作用.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
915
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
915
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
433
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
433
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.3K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.3K
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.3K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.3K
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
256
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
256
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.4K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.4K